

Ainnocence Unveils Advanced AAV Design Services to Revolutionize Gene Therapy

SAN FRANCISCO, CA, UNITED STATES, October 7, 2024 /EINPresswire.com/ -- Ainnocence, a next-generation biotech company, is proud to announce the launch of its cutting-edge AAV (Adeno-Associated Virus) design services, powered by the [SentinusAI®](#) platform. These services bring a host of advanced capabilities that address critical challenges in gene therapy development:

- **Tissue-Specific Targeting:** Tailored AAV vectors designed to target distinct tissue types by recognizing specific cell surface receptors, ensuring accurate gene delivery.
- **AI-Powered Ultra-High Throughput:** Capable of simultaneously optimizing multiple therapeutic targets, significantly speeding up the design process for various diseases.
- **No Structural Data Required:** Utilizing sequence-based protein language models, overcoming the need for target structure information, which has been a major industry bottleneck. This innovation allows the design of vectors for previously undruggable or flexible targets.
- **Rapid Turnaround:** Our highly efficient computational platform can deliver optimized AAV vectors in as little as one week, greatly reducing the time from concept to clinic-ready vectors.

Dr. Lurong Pan, CEO of Ainnocence, highlighted the breakthrough nature of these services: "Our AAV design services are a game-changer for gene therapy. We provide a revolutionary approach to tackling complex targets while drastically cutting down design times. This accelerates the development of life-saving therapies for patients who need them the most."

Ainnocence's SentinusAI® platform has already gained industry recognition for AI-driven drug discovery and protein engineering. With the addition of AAV design services, Ainnocence is poised to transform the future of gene therapy and bring innovative solutions to address a wide range of diseases, including rare genetic disorders and cancer.

About Ainnocence

Ainnocence is a biotech leader providing AI-powered drug discovery and therapeutic solutions across multiple industries, including biopharma, chemical, synthetic biology, and renewable energy. Its flagship platform, SentinusAI®, delivers rapid, precise solutions for protein engineering, antibody design, and AAV vector design, revolutionizing drug discovery. Ainnocence is committed to accelerating life-changing medical breakthroughs and fostering a healthier

future.

For more information, visit www.ainnocence.com, follow us on [LinkedIn](#), or leave us a [message](#).

Lurong Pan, PhD
Founder & CEO, Ainnocence
+1 205-249-7424
service@ainnocence.com

This press release can be viewed online at: <https://www.einpresswire.com/article/748042996>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.